Stockscreener 앱 받기
52.90
1.12%
-0.60
시간 외 거래:
52.89
-0.010
-0.02%
전일 마감가:
$53.50
열려 있는:
$53.21
하루 거래량:
8.97M
Relative Volume:
0.67
시가총액:
$7.09B
수익:
$640.44M
순이익/손실:
$-743.28M
주가수익비율:
-4.6861
EPS:
-11.2888
순현금흐름:
$-206.93M
1주 성능:
+30.78%
1개월 성능:
-9.68%
6개월 성능:
+21.58%
1년 성능:
+0.00%
1일 변동 폭
$52.22
$54.55
1주일 범위
$39.01
$54.55
52주 변동 폭
$22.89
$91.45
Tempus Ai Inc Stock (TEM) Company Profile
명칭
Tempus Ai Inc
전화
800-976-5448
주소
600 WEST CHICAGO AVENUE, CHICAGO
TEM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TEM
Tempus Ai Inc
|
52.90 | 7.09B | 640.44M | -743.28M | -206.93M | -11.29 |
|
VEEV
Veeva Systems Inc
|
227.54 | 34.18B | 2.75B | 714.14M | 1.09B | 4.33 |
|
DOCS
Doximity Inc
|
56.65 | 9.62B | 516.85M | 174.11M | 217.38M | 0.87 |
|
HQY
Healthequity Inc
|
85.87 | 6.94B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
37.02 | 6.06B | 906.14M | -52.62M | 89.62M | -0.3621 |
Tempus Ai Inc Stock (TEM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-21 | 개시 | BTIG Research | Buy |
| 2025-02-25 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-02-12 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-02-05 | 재개 | TD Cowen | Buy |
| 2024-12-13 | 개시 | Wolfe Research | Outperform |
| 2024-12-09 | 개시 | Guggenheim | Buy |
| 2024-11-11 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-10-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-08-12 | 개시 | Piper Sandler | Neutral |
| 2024-07-09 | 개시 | BofA Securities | Buy |
| 2024-07-09 | 개시 | JP Morgan | Overweight |
| 2024-07-09 | 개시 | Longbow | Buy |
| 2024-07-09 | 개시 | Loop Capital | Buy |
| 2024-07-09 | 개시 | Morgan Stanley | Overweight |
| 2024-07-09 | 개시 | Needham | Buy |
| 2024-07-09 | 개시 | Stifel | Buy |
| 2024-07-09 | 개시 | TD Cowen | Buy |
| 2024-07-09 | 개시 | William Blair | Outperform |
모두보기
Tempus Ai Inc 주식(TEM)의 최신 뉴스
Bitdeer Tech And Tempus AI Are Among Top 18 Mid-Cap Gainers Last Week (Apr 21-Apr 25): Are The Others In Your Portfolio? - Benzinga
Why Tempus AI Inc. (TEM) Soared Last Week - Insider Monkey
Tempus Announces 18 Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025 - 01net
Tempus AI Stock (TEM) Surges over 14% in a Day – What’s Next for Investors? - The Globe and Mail
The Zacks Analyst Blog Highlights Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS - Yahoo Finance
Tempus AI Stock Sees 21% Gain in 3 Days: Is it a Buy After AZN Deal? - MSN
Avidicure’s $50M seed round; Flagship’s new AI company that detects disease - Endpoints News
Tempus to Report First Quarter 2025 Financial Results on May 6 - Business Wire
Beyond The Numbers: 9 Analysts Discuss Tempus AI Stock - Benzinga
AstraZeneca enters $200m AI cancer pact with Tempus and Pathos - Pharmaceutical Technology
AstraZeneca joins Tempus, Pathos in cancer AI project - pharmaphorum
Tempus partners with AstraZeneca and Pathos for oncology AI model - World Pharmaceutical Frontiers
Tempus AI Reaches 80-Plus Relative Strength Rating Benchmark - inkl
These 10 Firms Topped Wednesday’s Trading - Insider Monkey
Tempus AI, Inc. (TEM): A Bull Case Theory - MSN
Why Tempus AI Inc. (TEM) Went Up On Wednesday - Insider Monkey
Tempus AI shares surge on new oncology partnerships By Investing.com - Investing.com India
Tempus AI shares surge on new oncology partnerships - Investing.com
Tempus expands partnership with AstraZeneca to build oncology model - MSN
AstraZeneca joins three-way $200M AI oncology deal - FirstWord Pharma
Tempus AI jumps after multi-year deals with AstraZeneca, Pathos AI - TradingView
Tempus AI Is Skyrocketing Today -- Is the Stock a Buy Right Now? - MSN
Is Tempus AI, Inc. (TEM) the Best Nancy Pelosi Stock To Invest In Now? - Insider Monkey
Tempus inks $200 million in AstraZeneca, Pathos AI deals for oncology model - Crain's Chicago Business
Discover Why Quantum Computing Stocks Are Soaring Today - 24/7 Wall St.
Tempus AI Shares Rise After Deals With AstraZeneca, Pathos AI - MarketWatch
Tempus AI shares jump on new oncology AI partnerships with AstraZeneca, Pathos - Proactive financial news
Why Tempus AI Stock Is Skyrocketing Today - MSN
Tempus Signs Expanded Strategic Agreements with Astrazeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology - marketscreener.com
Tempus expands partnership with AstraZeneca to build oncology model (TEM:NASDAQ) - Seeking Alpha
Tempus AI in line for $200M from AstraZeneca, Pathos deal to develop cancer model - Fierce Biotech
TempusAI (TEM) Enters Strategic Alliances with AstraZeneca and Pathos AI | AZN Stock News - GuruFocus
Tempus AI partners with AstraZeneca and Pathos on oncology AI - Investing.com
Tempus AI partners with AstraZeneca and Pathos on oncology AI By Investing.com - Investing.com India
Tempus AI announces oncology collaboration with AstraZeneca, Pathos AI - TipRanks
Tempus AI Inc Announces Strategic Collaborations With AstraZeneca And Pathos - TradingView
Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology - Business Wire
BTIG Initiates Coverage of Tempus AI (BMV:TEM) with Buy Recommendation - Nasdaq
Why Quantum Computing (QUBT), Nano Nuclear Energy (NNE) and Tempus AI (TEM) Are Popping Higher Today - MSN
Lobbying Update: $60,000 of TEMPUS AI INC. lobbying was just disclosed - Nasdaq
Tempus AI Options Trading: A Deep Dive into Market Sentiment - Nasdaq
Tempus AI (TEM) Initiated at ‘Buy’ with $60 Price Target by BTIG - Yahoo Finance
Tempus AI: Cooldown Arrived (Rating Upgrade) - Seeking Alpha
BTIG Initiates Coverage of Tempus AI (TEM) with Buy Recommendation - Nasdaq
BTIG Analyst Sees Tempus AI (TEM) as “Significant Free Call Option” with 48% Upside - markets.businessinsider.com
Tempus AI Gets Bullish Boost from BTIG on Data Strength, Expansion Moves - Yahoo Finance
BTIG sets Tempus stock Buy rating with $60 target By Investing.com - Investing.com Nigeria
BTIG sets Tempus stock Buy rating with $60 target - Investing.com Australia
Tempus AI initiated with a Buy at BTIG - Seeking Alpha
Tempus Ai Inc (TEM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.05%
0.70%
자본화:
|
볼륨(24시간):